Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Medications sold under brand names like Ozempic, Wegovy, and Saxenda have become famous for their weight-loss benefits, but ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 month ...

A diabetes medication that lowers brain fluid pressure has ... Headache Centre of the University of Naples “Federico II” gave ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...